MARKET

ATAI

ATAI

Atai Life Sciences B.V.
NASDAQ
1.610
-0.020
-1.23%
Closed 19:55 05/24 EDT
OPEN
1.650
PREV CLOSE
1.630
HIGH
1.650
LOW
1.590
VOLUME
565.75K
TURNOVER
0
52 WEEK HIGH
2.850
52 WEEK LOW
1.025
MARKET CAP
269.52M
P/E (TTM)
-6.7111
1D
5D
1M
3M
1Y
5Y
ATAI: Enormous Potential Upside But No Clarity Yet
Atai Life Sciences is an investment platform in the psychedelic drug industry. Shares in key competitors COMPASS Pathways and MindMed have shown signs of recovery. Major news items, such as FDA approval for MDMA-Assisted therapy and phase III data for COMP-360, are expected to impact the industry. Wall street analysts are forecasting a +600% share price increase for ATAI in the next 12 months.
Seeking Alpha · 1d ago
Weekly Report: what happened at ATAI last week (0520-0524)?
Weekly Report · 1d ago
Psychedelics Closer To Commercialization; Compass Far And Away The Leader
Psychedelics Closer To Commercialization; Compass Far And Away The Leader. Analyst Alex Carchidi discusses Compass, Cybin, Atai, and MindMed seeing improvements in their balance sheets and clinical trial data. Regulatory risk in the psychedelic industry is decreasing, which is a positive sign for investors. Institutional investors are becoming more willing to invest in leading psychedelic companies.
Seeking Alpha · 4d ago
Weekly Report: what happened at ATAI last week (0513-0517)?
Weekly Report · 05/20 11:57
ATAI Life Sciences Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Dow Jones · 05/17 17:26
HC Wainwright & Co. Reiterates Buy on ATAI Life Sciences, Maintains $15 Price Target
Benzinga · 05/17 17:16
Buy Rating Affirmed for ATAI Life Sciences Amid Promising TRD Treatment Developments and Strategic Growth Potential
TipRanks · 05/17 15:55
Buy Recommendation for ATAI Life Sciences Amidst Cost-Optimization and Promising Clinical Milestones
TipRanks · 05/17 10:35
More
About ATAI
ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company. The Company engages in developing various treatments that focuses on various mental health disorders. The Company's therapeutic lead compound include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder.

Webull offers ATAI Life Sciences NV stock information, including NASDAQ: ATAI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATAI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATAI stock methods without spending real money on the virtual paper trading platform.